Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Non-Muscle Invasive Bladder Neoplasms 3Carcinoma in Situ 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 10Mitomycin 6Docetaxel 5erdafitinib 4durvalumab 4BCG Vaccine 4dodecyl maltoside 3Cystoscopy 3ALT-803 2viscum album peptide 1tremelimumab 1pirarubicin 1monalizumab 1hydroxycamptothecinum 1chondroitin sulfate, sodium hyaluronate drug combination 1Watchful Waiting 1Transurethral Resection of Bladder 1Patient Discharge 1Mitozytrex 1Magnetic Resonance Spectroscopy 1Injections 1Hyaluronic Acid 1House Calls 1Home Care Services 1Epirubicin 1Drainage 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Chondroitin Sulfates 1Accelerometry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × dodecyl maltoside × 90 days × Clear all
NCT07283835 2026-04-23

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Lepu Biopharma Co., Ltd.

Phase 2 Recruiting
16 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

CG Oncology, Inc.

Available
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT04452591 2026-03-16

BOND-003

CG Oncology, Inc.

Phase 3 Active not recruiting
190 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡